Business
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee – – In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate to 95% – – NEXICART-2 final readout and BLA submission planned in 2026 – LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory
About this update from Immix Biopharma, Inc.
[{"type":"image","alt":"Immix Biopharma, Inc.","displaySize":"","headline":null,"caption":"Immix Biopharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":93,"url":"https://media.zenfs.com/en/globenewswire.com/2c6c1d83bafb554be7762f3727be359d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wOmQhF0jrEFCj3SbuTNPPg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/2c6c1d83bafb554be7762f3727be359d","width":300,"height":93}},"lazy":false},{"type":"text","content":"– NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee –","length":123,"tagName":"p"},{"type":"text","content":"– In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate to 95% –","length":151,"tagName":"p"},{"type":"text","content":"– NEXICART-2 final readout and BLA submission planned in 2026 –","length":63,"tagName":"p"},{"type":"text","content":"LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced positive phase 2 NXC-201 results in an oral presentation at ASH 2025 presented by Heather Landau, MD, of Memorial Sloan Kettering Cancer Center. NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee. In four out of five pending patients, MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate to 95%. NEXICART-2 final readout and BLA submission are planned for 2026.","length":673,"tagName":"p"},{"type":"text","content":"“In the larger patient set Phase 2 results presented today at ASH, we are thrilled to see complete response rates continue to improve in NEXICART-2. These excellent results demonstrate the potential of NXC-201 to address the significant unmet medical need in relapsed/refractory AL Amyloidosis,” said Ilya Rachman, MD, PhD, Chief Executive Officer of Immix Biopharma. Gabriel Morris, Chief Financial Officer of Immix Biopharma, added, “This exciting Phase 2 milestone brings us one step closer to delivering this promising therapy to patients upon planned BLA submission in 2026.”","length":580,"tagName":...